| Literature DB >> 35855806 |
Tuanyu Fang1, Leweihua Lin1, Qianying Ou1, Lu Lin1, Huachuan Zhang1, Kaining Chen1, Huibiao Quan1, Yangli He2.
Abstract
Background: In recent years, the incidence of thyroid diseases has increased significantly, which has seriously affected people's work and life. The purpose of this study was to explore the epidemiological characteristics of thyroid diseases and autoantibodies. Method: According to the principle of overall sampling, resident residents ≥18 years and who will not move within 5 years are randomly selected. A total of 2136 eligible individuals were divided into case and control groups according to whether they have thyroid disease. Finally, the impact of potential risk factors on thyroid diseases was evaluated.Entities:
Year: 2022 PMID: 35855806 PMCID: PMC9288325 DOI: 10.1155/2022/4514538
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 2.803
Characteristics of subjects.
| Item | Thyroid cases ( | Normal ( |
|---|---|---|
| Gender | ||
| Male | 329 (26.4%) | 380 (42.6%) |
| Female | 916 (73.6%) | 511 (57.4%) |
| Age | ||
| Mean ± SD | 49.55 ± 0.38 | 44.86 ± 0.46 |
| 18–29 | 107 (8.6%) | 141 (15.8%) |
| 30–39 | 193 (15.5%) | 201 (22.6%) |
| 40–49 | 270 (21.7%) | 199 (22.3%) |
| 50–59 | 415 (33.3%) | 216 (24.2%) |
| 60–69 | 192 (15.4%) | 108 (12.1%) |
| ≥70 | 68 (5.5%) | 26 (2.9%) |
| BMI | ||
| BMI < 18.5 | 66 (5.3%) | 50 (5.6%) |
| 18.5 ≤ BMI < 24 | 616 (49.5%) | 469 (52.6%) |
| 24 ≤ BMI < 28 | 425 (34.1%) | 289 (32.4%) |
| BMI ≥ 28 | 138 (11.1%) | 83 (9.3%) |
| WC (cm) | ||
| Male ≥ 95 and female ≥ 90 | 631 (50.7%) | 455 (51.1%) |
| 85 ≤ male < 95 and 80 ≤ female < 90 | 543 (43.6%) | 377 (42.3%) |
| Male < 85 and female < 80 | 71 (5.7%) | 59 (6.6%) |
| WHtR | 0.51 ± 0.06 | 0.50 ± 0.06 |
| Height | 158.23 ± 0.23 | 160.39 ± 0.28 |
| Weight | 59.73 ± 0.32 | 60.75 ± 0.40 |
| Systolic blood pressure | 125.04 ± 0.59 | 123.15 ± 0.65 |
| Diastolic blood pressure | 78.23 ± 0.36 | 77.75 ± 0.39 |
| Heart rate | 81.89 ± 0.37 | 80.98 ± 0.39 |
| TSH | 2.85 ± 0.17 | 1.92 ± 0.03 |
| Serum vitamin D3 | 37.12 ± 0.32 | 38.42 ± 0.44 |
| Triglycerides | 1.83 ± 0.05 | 1.92 ± 0.07 |
| Total cholesterol | 5.43 ± 0.03 | 5.34 ± 0.04 |
| LDL | ||
| Mean ± SD | 2.95 ± 0.02 | 2.87 ± 0.03 |
| Low | 11 (0.9%) | 17 (1.9%) |
| High | 708 (56.9%) | 535 (60%) |
| Normal | 526 (42.2%) | 339 (38%) |
| HDL | 1.53 ± 0.01 | 1.50 ± 0.01 |
| Uric acid | 348.89 ± 2.44 | 359.2 ± 2.99 |
BMI: body mass index; WC: waist circumference; WHtR: waist-height ratio; SD: standard deviation; TSH: thyroid stimulating hormone; LDL: low-density lipoprotein; HDL: high-density lipoprotein. “” and bold text represent statistical significance.
Gender differences in the prevalence of different thyroid diseases.
| Item | Prevalence | Total |
| |
|---|---|---|---|---|
| Male | Female | |||
| Thyroid dysfunction |
| |||
| Hypothyroidism | 1 (0.3%) | 26 (2.8%) | 27 (2.2%) | |
| Subclinical hypothyroidism | 34 (10.3%) | 130 (14.2%) | 164 (13.2%) | |
| Thyroid hyperfunction | ||||
| Hyperthyroidism | 8 (2.4%) | 22 (2.4%) | 30 (2.4%) | |
| Subclinical hyperthyroidism | 3 (0.9%) | 21 (2.3%) | 24 (1.9%) | |
| Thyroid cancer | 3 (0.9%) | 9 (1.0%) | 12 (1.0%) | |
| Thyroma | 1 (0.3%) | 2 (0.2%) | 3 (0.2%) | |
| Thyroid nodules | 233 (70.8%) | 538 (58.7%) | 771 (61.9%) | |
| Thyroid antibody positive | 46 (14.0%) | 168 (18.3%) | 214 (17.2%) | |
“” and bold text represent statistical significance.
Comparison of gender differences in the prevalence of thyroid diseases in different age groups.
| Age (years) | Male | Female | Total |
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| Prevalence (%) |
|
| Prevalence (%) |
|
| Prevalence (%) | |||
| 18–29 | 72 | 24 | 33.33 | 176 | 83 | 47.16 | 248 | 107 | 43.15 | 3.98 |
|
| 30–39 | 130 | 43 | 33.08 | 264 | 150 | 56.82 | 394 | 193 | 48.98 | 19.65 |
|
| 40–49 | 146 | 64 | 43.84 | 323 | 206 | 63.78 | 469 | 270 | 57.57 | 16.37 |
|
| 50–59 | 215 | 117 | 54.42 | 416 | 298 | 71.63 | 631 | 415 | 65.77 | 18.66 |
|
| 60–69 | 110 | 58 | 52.73 | 190 | 134 | 70.53 | 300 | 192 | 64.00 | 9.58 |
|
| ≥70 | 36 | 23 | 63.89 | 58 | 45 | 77.59 | 94 | 68 | 72.34 | 2.08 | 0.149 |
| Total | 709 | 329 | 46.40 | 1427 | 916 | 64.19 | 2136 | 1245 | 58.29 | 61.64 |
|
N: number. “” and bold text represent statistical significance.
Figure 1Prevalence of thyroid diseases in different age groups.
Differences of thyroid prevalence under different obesity parameters.
| Item | Total | BMI | Central obesity | ||||
|---|---|---|---|---|---|---|---|
| Normal (18.5 ≤ BMI < 24) | Underweight (<18.5) | Overweight (24 ≤ BMI < 28) | Obesity (≥28) | Yes | No | ||
| Thyroid dysfunction | |||||||
| Hypothyroidism | 27 | 11 (40.7%) | 1 (3.7%) | 10 (37%) | 5 (18.5%) | 9 (33.3%) | 18 (66.7%) |
| Subclinical hypothyroidism | 164 | 82 (50.0%) | 11 (6.7%) | 52 (31.7%) | 19 (11.6%) | 44 (26.8%) | 120 (73.2%) |
| Thyroid hyperfunction | |||||||
| Hyperthyroidism | 30 | 17 (56.7%) | 5 (16.7%) | 8 (26.7%) | 0 (0%) | 2 (6.7%) | 28 (93.3%) |
| Subclinical hyperthyroidism | 24 | 10 (41.7%) | 2 (8.3%) | 10 (41.7%) | 2 (8.3%) | 5 (20.8%) | 19 (79.2%) |
| Thyroid cancer | 12 | 3 (25.0%) | 1 (8.3%) | 5 (41.7%) | 3 (25%) | 5 (41.7%) | 7 (58.3%) |
| Thyroid nodules | 771 | 366 (47.5%) | 28 (3.6%) | 282 (36.6%) | 95 (12.3%) | 264 (34.2%) | 507 (65.8%) |
| Positive thyroid antibody | 214 | 124 (57.9%) | 18 (8.4%) | 58 (27.1%) | 14 (6.5%) | 44 (20.6%) | 170 (79.4%) |
| Thyroma | 3 | 3 (100.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (100.0%) |
| Normal | 891 | 469 (52.6%) | 50 (5.6%) | 289 (32.4%) | 83 (9.3%) | 218 (24.5%) | 673 (75.5%) |
|
| — | — | 11.33 | 15.21 | 21.70 | 36.59 | |
|
| — | — | 0.184 | 0.055 |
|
| |
BMI: body mass index; WC: waist circumference. Central obesity: male waist circumference ≥90 cm and female waist circumference ≥85 cm. “” and bold text represent statistical significance.
The difference of thyroid disease between recessive and positive autoantibody groups.
| Item | TPOAb | TgAb | ||
|---|---|---|---|---|
| + (%) | −(%) | + (%) | −(%) | |
| Thyroid dysfunction | ||||
| Hypothyroidism | 12 (2.9%) | 22 (1.3%) | 1 (0.3%) | 26 (1.4%) |
| Subclinical hypothyroidism | 31 (7.4%) | 133 (7.8%) | 26 (8.3%) | 138 (7.6%) |
| Thyroid hyperfunction | ||||
| Hyperthyroidism | 6 (1.4%) | 24 (1.4%) | 7 (2.2%) | 23 (1.3%) |
| Subclinical hyperthyroidism | 16 (3.8%) | 20 (1.2%) | 1 (0.3%) | 23 (1.3%) |
| Thyroid cancer | 2 (0.5%) | 10 (0.6%) | 0 (0%) | 12 (0.7%) |
| Thyroid nodules | 141 (33.7%) | 628 (36.6%) | 113 (36.1%) | 656 (36.2%) |
| Positive thyroid antibody | 46 (11%) | 168 (9.8%) | 45 (14.4%) | 169 (9.3%) |
| Thyroma | 1 (0.2%) | 2 (0.1%) | 0 (0%) | 3 (0.2%) |
| Total | 255 (61.0%) | 1007 (58.7%) | 193 (61.7%) | 1050 (57.9%) |
|
|
|
| ||
TPOAb: thyroid peroxidase antibody; TgAb: thyroglobulin antibody; “+”: positive autoantibody; “−”: negative autoantibodies. “” and bold text represent statistical significance.
Comparison of gender differences in autoantibody positive rates in different age groups.
| Age (years) | TPOAb (+) |
| TgAb (+) |
| ||
|---|---|---|---|---|---|---|
| Male | Female | Male | Female | |||
| 18–29 | 17 (11.7%) | 38 (13.9%) | 0.944 | 7 (7.1%) | 28 (13.1%) | 0.463 |
| 30–39 | 30 (20.7%) | 51 (18.7%) | 17 (17.2%) | 42 (19.6%) | ||
| 40–49 | 31 (21.4%) | 63 (23.1%) | 22 (22.2%) | 54 (25.2%) | ||
| 50–59 | 44 (30.3%) | 74 (27.1%) | 35 (35.4%) | 60 (28.0%) | ||
| 60–69 | 16 (11.0%) | 31 (11.4%) | 14 (14.1%) | 23 (10.7%) | ||
| ≥70 | 7 (4.8%) | 16 (5.9%) | 4 (4.0%) | 7 (3.3%) | ||
| Total | 145 (34.7%) | 273 (65.3%) | 99 (31.6%) | 214 (68.4%) | ||
TPOAb: thyroid peroxidase antibody; TgAb: thyroglobulin antibody; “+”: positive autoantibody; “−”: negative autoantibodies.
Figure 2(a) Positive rates of autoantibodies in different age groups. (b) Positive rates of autoantibodies in different gender groups.
Differences of four thyroid hormones in different genders.
| Gender | UIC (ug/L) |
|
| TSH (mIU/L) |
|
| FT4 (pmol/L) |
|
| FT3 (pmol/L) | U |
| ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | (P25, P75) | Median | (P25, P75) | Median | (P25, P75) | Median | (P25, P75) | |||||||||
| Male | 159.32 | (107.23, 221.92) | 461226.5 |
| 1.67 | (1.21, 2.45) | 459022.5 |
| 17.14 | (15.01, 19.50) | 3428.5 |
| 7.35 | (5.67, 9.90) | 239.0 | 0.444 |
| Female | 147.30 | (89.09, 223.74) | 1.88 | (1.23, 2.90) | 15.5 | (13.48, 17.73) | 6.15 | (4.91, 8.75) | ||||||||
UIC: urinary iodine concentration; TSH: thyroid stimulating hormone; FT4: free thyroxine; FT3: free triiodothyronine. “” and bold text represent statistical significance.
Figure 3Prevalence of thyroid diseases in different UIC levels.
The influence of different urine iodine concentration on the prevalence of thyroid diseases.
| UIC ( |
| Thyroid cases | Prevalence (%) | |
|---|---|---|---|---|
| Yes | No | |||
| 0∼ | 156 | 101 | 55 | 64.7 |
| 50∼ | 294 | 203 | 91 | 69.0 |
| 100∼ | 292 | 181 | 111 | 62.0 |
| 150∼ | 275 | 161 | 114 | 58.5 |
| 200∼ | 279 | 142 | 137 | 50.9 |
| 250∼ | 158 | 71 | 87 | 44.9 |
| 300∼ | 165 | 91 | 74 | 55.2 |
| 350∼ | 129 | 64 | 65 | 49.6 |
| 400∼ | 166 | 83 | 83 | 50.0 |
| 450∼ | 132 | 78 | 54 | 59.1 |
| 500∼ | 90 | 70 | 20 | 77.8 |
| Total | 2136 | 1245 | 891 | 58.3 |
N: number; UIC: urinary iodine concentration.
Multivariate logistic regression analysis of the prevalence of thyroid diseases.
| Variables |
| S.E. | Wald |
| OR | 95%CI |
|---|---|---|---|---|---|---|
| Gender | ||||||
| Male (ref) | ||||||
| Female | 0.91 | 0.16 | 31.45 |
| 2.49 | 1.81–3.43 |
| Age | ||||||
| 18–29 (ref) | <0.001 | |||||
| 30–39 | 1.65 | 0.47 | 12.28 | 0.213 | 1.44 | 2.07–13.06 |
| 40–49 | 1.13 | 0.43 | 6.80 |
| 2.44 | 1.32–7.22 |
| 50–59 | 0.89 | 0.43 | 4.34 |
| 3.09 | 1.05–5.63 |
| 60–69 | 0.52 | 0.42 | 1.55 |
| 5.20 | 0.74–3.85 |
| ≥70 | 0.44 | 0.44 | 0.99 | 0.319 | 1.55 | 0.66–3.66 |
| BMI | ||||||
| 18.5 ≤ BMI < 2 (ref) | 0.320 | |||||
| BMI<18.5 | −0.30 | 0.40 | 0.57 | 0.452 | 0.74 | 0.34–1.63 |
| 24 ≤ BMI<28 | 0.19 | 0.28 | 0.44 | 0.506 | 1.20 | 0.70–2.08 |
| BIM ≥ 28 | −0.04 | 0.28 | 0.02 | 0.876 | 0.96 | 0.55–1.66 |
| Smoking | ||||||
| Yes (ref) | ||||||
| No | 0.24 | 0.24 | 0.93 | 0.335 | 1.27 | 0.78–2.04 |
| Region | ||||||
| Suburb (ref) | ||||||
| Urban | 0.07 | 0.17 | 0.15 | 0.696 | 1.07 | 0.77–1.48 |
| Season | ||||||
| Spring (ref) | 2.05 | 0.562 | ||||
| Summer | −0.03 | 0.21 | 0.02 | 0.881 | 0.97 | 0.64–1.47 |
| Autumn | −0.26 | 0.21 | 1.63 | 0.201 | 0.77 | 0.51–1.15 |
| Winter | 0.07 | 0.24 | 0.08 | 0.777 | 1.07 | 0.66–1.73 |
| Family history of thyroid disease | ||||||
| Yes (ref) | ||||||
| No | −0.85 | 0.23 | 13.96 |
| 0.43 | 0.27–0.67 |
| Hyperlipidemia | ||||||
| Yes (ref) | ||||||
| No | −0.15 | 0.20 | 0.56 | 0.456 | 0.86 | 0.58–1.28 |
| Hyperuric acidemia | ||||||
| Yes (ref) | ||||||
| No | −0.01 | 0.17 | 0.00 | 0.968 | 0.99 | 0.71–1.39 |
| Hypertension | ||||||
| No (ref) | ||||||
| Yes | 0.15 | 0.18 | 0.68 | 0.409 | 1.16 | 0.82–1.65 |
| Gout disease | ||||||
| No (ref) | ||||||
| Yes | 0.13 | 0.23 | 0.33 | 0.567 | 1.14 | 0.72–1.81 |
| TPOAb | ||||||
| − (ref) | ||||||
| + | 0.43 | 0.22 | 3.74 | 0.053 | 1.54 | 0.99–2.38 |
| TgAb | ||||||
| − (ref) | ||||||
| + | −0.36 | 0.25 | 2.15 | 0.143 | 0.70 | 0.43–1.13 |
| Triglyceride | ||||||
| Normal (ref) | 2.38 | 0.304 | ||||
| L | 0.26 | 0.43 | 0.36 | 0.547 | 1.30 | 0.56–3.00 |
| H | 0.24 | 0.16 | 2.20 | 0.138 | 1.27 | 0.92–1.75 |
| Total cholesterol | ||||||
| Normal (ref) | 0.15 | 0.926 | ||||
| L | −0.09 | 1.07 | 0.01 | 0.934 | 0.92 | 0.11–7.41 |
| H | −0.06 | 0.16 | 0.15 | 0.699 | 0.94 | 0.69–1.29 |
| LDL | ||||||
| Normal (ref) | 0.91 | 0.635 | ||||
| H | 0.17 | 0.18 | 0.86 | 0.354 | 1.18 | 0.83–1.68 |
| HDL | ||||||
| Normal (ref) | ||||||
| L | 0.51 | 0.63 | 0.65 | 0.420 | 1.66 | 0.49–5.67 |
| H | −0.08 | 0.16 | 0.21 | 0.647 | 0.93 | 0.67–1.28 |
| Serum vitamin D3 | ||||||
| Inadequate | ||||||
| Amplitude | 0.01 | 0.18 | 0.01 | 0.939 | 1.01 | 0.71–1.44 |
TPOAb: thyroid peroxidase antibody; TgAb: thyroglobulin antibody; “+”: positive autoantibody; “−”: negative autoantibodies; LDL: low-density lipoprotein; HDL: high-density lipoprotein. “” and bold text represent statistical significance. “” and bold text represent statistical significance.